“Astellas Pharma Inc. (Tokyo: 4503) and Potenza Therapeutics, Inc., a biotechnology company developing a portfolio of immuno-oncology programs, today announced an exclusive research and development collaboration. The goal of the collaboration is to advance a portfolio consisting of programs with n
“Astellas Pharma Inc. (Tokyo: 4503) and Potenza Therapeutics, Inc., a biotechnology company developing a portfolio of immuno-oncology programs, today announced an exclusive research and development collaboration. The goal of the collaboration is to advance a portfolio consisting of programs with n
このブックマークにはスターがありません。
最初のスターをつけてみよう！
Astellas Pharma And Potenza Therapeutics Partner To Build A Portfolio Of Immuno-Oncology Therapeutics
1 人がブックマーク・1 件のコメント
＼ コメントが サクサク読める アプリです ／